Home/Pipeline/CUE-401

CUE-401

Autoimmune and Inflammatory Diseases

PreclinicalActive

Key Facts

Indication

Autoimmune and Inflammatory Diseases

Phase

Preclinical

Status

Active

Company

Cue Biopharma

About Cue Biopharma

Cue Biopharma is developing precision immunotherapies using its Immuno-STAT™ platform to selectively engage and modulate specific T cell populations, with an initial focus on autoimmune conditions and cancer. The company has established strategic collaborations with industry leaders like Boehringer Ingelheim and is advancing its lead asset, CUE-401, toward clinical development. Despite a challenging financial position with a low market valuation, its targeted approach represents a differentiated strategy in the competitive biologics landscape.

View full company profile

Therapeutic Areas

Autoimmune Diseases Oncology

Other Autoimmune and Inflammatory Diseases Drugs

Drug	Company	Phase	Status
CUG252	Cugene	Pre-clinical	Active
Foldikine™ Platform Pipeline	Orikine Bio	Preclinical	Active
CD31-ITAM Bispecific Platform	Tridek-One	Pre-clinical	Active